Home › NDC Lookup › RxCUI directory › RxCUI 2667941

Baclofen 2 MG/ML Oral Solution — RxCUI 2667941

RxNorm drug concept · Semantic clinical drug
RxCUI 2667941 Semantic clinical drug · SCD ● Current RxNorm concept 6 FDA products 9 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2667941
Official nameBaclofen 2 MG/ML Oral Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asbaclofen 10 MG per 5 mL Oral Solution; baclofen 10 MG in 5 mL Oral Solution
FDA products mapped6
Package NDCs mapped9
Reported Medicaid activity (SDUD)7,415 prescriptions · 40 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Baclofen: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It eases spasticity, meaning stiff, tight muscles and spasms. Oral forms are used mainly for spasticity from multiple sclerosis and may help with spinal cord injuries. Intrathecal...
  • Oral baclofen is usually started low and split into several doses a day, then increased slowly. Follow your prescriber and label. With liquids, double-check both the mg and mL on y...
  • Don't stop suddenly. Your dose should be lowered slowly. With an intrathecal pump, missing a refill can cause dangerous withdrawal, so keep every appointment.
  • Sleepiness, dizziness, nausea, headache, low blood pressure and muscle weakness are common. Avoid driving until you know how it affects you, and avoid alcohol.
📖 Read our full Baclofen guide →

🕸️ Concept Web — How Baclofen 2 MG/ML Oral Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Baclofen 2 MG/ML Oral Solution RxCUI 2667941

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Baclofen 1292
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ozobax 2201573
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Baclofen Oral Solution 370984
    • Baclofen Oral Liquid Product 1155669
    • Baclofen Oral Product 1155670
    • Baclofen Oral Solution [Ozobax] 2201575
    • Ozobax Oral Liquid Product 2201576
    • Ozobax Oral Product 2201577
    • Oral Solution 316968
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Baclofen 2 MG/ML SCDC · 315457
  • Baclofen Oral Solution SCDF · 370984
  • Baclofen Oral Liquid Product SCDG · 1155669
  • Baclofen Oral Product SCDG · 1155670

Brand-Name Concepts

  • Baclofen 2 MG/ML Oral Solution [Ozobax] SBD · 2667943
  • Baclofen 2 MG/ML [Ozobax] SBDC · 2667942
  • Baclofen Oral Solution [Ozobax] SBDF · 2201575
  • Ozobax Oral Liquid Product SBDG · 2201576
  • Ozobax Oral Product SBDG · 2201577
  • Ozobax BN · 2201573

📦 FDA Products & Package NDCs

6 products · 9 package NDCs
9 package NDCs map to RxCUI 2667941 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
17856-0620-01 72 CUP, UNIT-DOSE in 1 CASE (17856-0620-1) / 2.5 mL in 1 CU... Baclofen Atlantic Biologicals Corp. 2026-04-30
17856-0620-02 72 CUP, UNIT-DOSE in 1 CASE (17856-0620-2) / 5 mL in 1 CUP,... Baclofen Atlantic Biologicals Corp. 2026-04-30
52817-0620-08 237 mL in 1 BOTTLE (52817-620-08) Baclofen TRUPHARMA, LLC 2023-10-12
68134-0403-16 473 mL in 1 BOTTLE (68134-403-16) Baclofen Palmetto Pharmaceuticals Inc. 2024-09-25
69528-0302-08 237 mL in 1 BOTTLE (69528-302-08) OZOBAX DS Rosemont Pharmaceuticals LLC 2023-10-12
69528-0302-16 473 mL in 1 BOTTLE (69528-302-16) OZOBAX DS Rosemont Pharmaceuticals LLC 2023-10-12
72834-0602-16 473 mL in 1 BOTTLE (72834-602-16) Baclofen Rosemont Pharmaceuticals LLC 2024-03-05
72888-0466-01 473 mL in 1 BOTTLE (72888-466-01) Baclofen Advagen Pharma Ltd., 2025-06-03
72888-0466-02 237 mL in 1 BOTTLE (72888-466-02) Baclofen Advagen Pharma Ltd., 2025-06-03
Observed labelers: Rosemont Pharmaceuticals LLC (3) · Advagen Pharma Ltd., (2) · Atlantic Biologicals Corp. (2) · Palmetto Pharmaceuticals Inc. (1) · TRUPHARMA, LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$2.1650
Range $2.1650–$2.1650 · middle 50% $2.1650–$2.1650 · 2 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.